BioPharma Resources

Drug Trial Radar · NCT06647498

A Study of a Potential Disease Modifying Treatment in Individuals at Risk for or With a Type of Early Onset AD Caused by a Genetic Mutation

A Phase II/III Multicenter Randomized, Double-Blind, Placebo-Controlled, Two-Stage Adaptive Design, Platform Trial of Investigational Treatments for Primary Prevention of Disease Progression in Dominantly Inherited Alzheimer's Disease

Last checked: Nov 19, 2026Latest source record: Nov 19, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

RecruitingPivotal-lookingPhase 3. Randomized with 280 participants. This is a heuristic, not a regulatory label.

Status

Recruiting

Enrollment

280

Planned (sponsor's estimate)

Start

Nov 22, 2024

Primary completion

Mar 2034

Study completion Aug 2034

Sponsor

Lead sponsor
Washington University School of MedicineAcademic, hospital or other
Sponsor type
Academic, hospital or other
Collaborators
Alzheimer's Association; Eli Lilly and Company; National Institute on Aging (NIA); GHR Foundation; Private Donors
First posted
Oct 17, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
Yes

Summary

As written by the sponsor on the registry.

The purpose of this research study is to test the study drug, referred to as remternetug, to determine its effectiveness for the study treatment of asymptomatic (at risk) Alzheimer disease in individuals with AD-causing mutations. This study will also investigate the effects of remternetug on biomarkers (measures of the disease including brain scans, blood and spinal fluid tests), examine safety data to identify any potential benefits or risks, and examine how well participants can tolerate remternetug. Stage 1 will determine if treatment with the study drug prevents or reverses amyloid beta (Aβ) accumulation compared with placebo in participants with dominantly inherited Alzheimer's disease (DIAD). Stage 2 will evaluate the effect of early anti-amyloid treatment on downstream biomarkers of AD in treated participants compared to external control groups.

Conditions

  • Alzheimers Disease
  • Dementia
  • Alzheimers Disease, Familial

Interventions

  • RemternetugDrug

    Administered subcutaneously every 12 weeks

  • Matching Placebo (Remternetug)Drug

    Administered as subcutaneous injection of placebo every 12 weeks

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Stage 1: Change in amyloid load as measured by centiloid (CL) [11C]PiB-PET as biomarker endpoint for DIAN-TU-002 remternetug armTime frame: Baseline and Week 192

Locations

36 sites in 14 countries. Site status is shown where the registry gives one.

  • University of Alabama in Birmingham

    Birmingham, Alabama · Recruiting

  • University of California San Diego Medical Center

    La Jolla, California · Recruiting

  • University of Southern Califonria

    Los Angeles, California · Recruiting

  • Yale University School of Medicine

    New Haven, Connecticut · Recruiting

  • Emory University

    Atlanta, Georgia · Recruiting

  • Advocate Lutheran General Hospital

    Park Ridge, Illinois · Recruiting

  • Indiana University School of Medicine

    Indianapolis, Indiana · Recruiting

  • Washington University in St. Louis

    St Louis, Missouri · Recruiting

  • New York University Medical Center

    New York, New York · Recruiting

  • University of Pittsburgh

    Pittsburgh, Pennsylvania · Recruiting

  • Butler Hospital

    Providence, Rhode Island · Recruiting

  • Kerwin Research and Memory Center

    Dallas, Texas · Recruiting

  • University of Washington

    Seattle, Washington · Recruiting

  • Instituto de Investigaciones Neurologicas Raul Carrea, FLENI

    Ciudad Autonoma de Buenos Aire, Argentina · Recruiting

  • Neuroscience Research Australia

    Randwick, New South Wales, Australia · Recruiting

  • Alzheimer's Research Australia

    Melbourne, Victoria, Australia · Recruiting

  • CHU de Quebec - Hôpital de l' Enfant Jésus

    Québec, Canada · Recruiting

  • UBC Hospital

    Vancouver, British Columbia, Canada · Recruiting

  • Sunnybrook Health Sciences Centre

    Toronto, Ontario, Canada · Recruiting

  • McGill Center for Studies in Aging

    Verdun, Quebec, Canada · Recruiting

  • Grupo de Neurociencias Sede de la Universidad de Antioquia

    Medellín, Colombia · Recruiting

  • CHU de Toulouse - Hôpital Purpan

    Toulouse, Haute Garonne, France · Not yet recruiting

  • Hopital Roger Salengro - CHU Lille

    Lille, Nord, France · Not yet recruiting

  • Groupe Hospitalier Pitie-Salpetriere

    Paris, Paris, France · Not yet recruiting

  • Hopital Neurologique Pierre Wertheimer

    Bron, Rhone, France · Not yet recruiting

  • CHU de Rouen - Hôpital Charles Nicolle

    Rouen, Seine Maritime, France · Recruiting

  • Universitaetsklinikum Tubingen

    Tübingen, Baden-Wurttemberg, Germany · Recruiting

  • LMU-Campus Grosshadern

    Munich, Bavaria, Germany · Recruiting

  • IRCCS Centro San Giovanni di Dio Fatebenefratelli

    Brescia, Italy · Recruiting

  • Azienda Ospedaliera Universitaria Careggi

    Florence, Italy · Recruiting

  • Instituto Nacional de Neurologia y Neurocirugia Manuel Velasco Suarez

    Mexico City, Mexico City, Mexico · Not yet recruiting

  • New Zealand Brain Research Institute

    Christchurch, New Zealand · Recruiting

  • University of Puerto Rico, School of Medicine

    San Juan, Puerto Rico, Puerto Rico · Recruiting

  • Asan Medical Center

    Seoul, South Korea · Not yet recruiting

  • Hospital Clínic I Provincial de Barcelona

    Barcelona, Barcelona, Spain · Recruiting

  • The National Hospital for Neurology and Neurosurgery

    London, Greater London, United Kingdom · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.